NEW

Study Confirms Surfacide UV-C Kills SARS-CoV-2

A recent peer-reviewed study in the Journal of Clinical Anesthesia* found the Surfacide Helios® System UV-C technology is nearly 95% effective in preventing SARS CoV-2 in patient environments. This is the first clinical study that evaluates the use of UV-C in...

AORN Recommends Nasal Decolonization with PVP-I

The Association of periOperative Registered Nurses (AORN) has announced its annual updated recommendations on the "Guideline for Preoperative Skin Antisepsis," to assist health care professionals in navigating risk-based decisions for developing preoperative...

New AAAHC Quality Roadmap Probes Data, Highlights Surveyor Insights

On June 16, AAAHC released its 2021 Quality Roadmap, a comprehensive analysis of data from more than 1,120 accreditation surveys conducted in 2020.

RSIP Vision Reveals New Module

RSIP Vision has announced its new surgical workflow analysis technology, which can intelligently identify each separate stage of a surgical procedure and label them accordingly throughout the duration of the procedure.

USMI Developing the First Surgical Robot for Cancer Surgery

USMI Canady Surgical System

US Medical Innovations LLC (USMI) announced that it is developing the first robotic delivery system used for cancer surgery.

The new Canady Surgical System (CSS) is a space-efficient, cost-effective, stand-alone solution for robotic assisted surgery during open, laparoscopic/mini-invasive, endoscopic, thoracoscopic and trans-oral surgical procedures.

Features of the new Canady Surgical System include Voice Command technology which frees up the surgeon and assistant to focus on the surgical procedure and perform other tasks. The system includes both Canady Hybrid Plasma (CHP) and Canady Helios Cold Atmospheric Plasma (CHCAP) as well as a flexible disposable scope and camera system.

Preloaded in the CSS are treatment-dosage protocols for over 30 different cancer types and a robotic assisted image-guided navigational mapping system that delivers personalized and targeted CHCAP cancer treatments directly to the surgical site and ablating any remaining cancer cells after the tumor is removed with the CHP.

According to Jerome Canady, MD, and CEO of USMI, “Our CHCAP technology actually ablates cancer cells without damaging surrounding healthy tissue. We recently completed a Phase 1 FDA Clinical Trail using Canady Helios™ Cold Atmospheric Plasma (CHCAP) for the treatment of recurrent and stage 4 solid tumors. We see this novel technology, delivered with the precision of robotic assisted technology, as the most exciting new form of personalized and targeted medicine being explored today.”

CHCAP has many advantages. It is performed during the surgical procedure. It is highly selective because it only targets cancer cells. And thirdly, the CHCAP treatment is personalized for specific cancer types (i.e., breast, ovarian, sarcoma, lung, colon, cervical, pancreas and other solid cancerous tumors).

The organization expects to have the new Canady Surgical System in clinical trials later this year. Protocols and site locations are being explored at this time.

For more information, visit www.usmedinnovations.com.

Previous

Next

Submit a Comment

Your email address will not be published. Required fields are marked *

X